Amplifying Cancer Immunity: AMPK Activators and Gammadelta T Cells Unveiled
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Guigas B, Viollet B
. Targeting AMPK: From Ancient Drugs to New Small-Molecule Activators. Exp Suppl. 2016; 107:327-350.
DOI: 10.1007/978-3-319-43589-3_13.
View
2.
Anagnostakis F, Piperi C
. Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas. Curr Neuropharmacol. 2022; 21(3):457-470.
PMC: 10207914.
DOI: 10.2174/1570159X20666220120120203.
View
3.
Mensurado S, Blanco-Dominguez R, Silva-Santos B
. The emerging roles of γδ T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023; 20(3):178-191.
DOI: 10.1038/s41571-022-00722-1.
View
4.
Close H, Stead L, Nsengimana J, Reilly K, Droop A, Wurdak H
. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clin Exp Immunol. 2019; 200(1):33-44.
PMC: 7066386.
DOI: 10.1111/cei.13403.
View
5.
Rigau M, Ostrouska S, Fulford T, Johnson D, Woods K, Ruan Z
. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science. 2020; 367(6478).
DOI: 10.1126/science.aay5516.
View